MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MABTENANCE
- 16 Feb 2018 The study has been completed in Bulgarian (End Date:2017-11-28) according to European Clinical Trials Database.
- 05 Feb 2018 The study has been completed in Slovakia (End Date:2017-11-28).
- 15 Jan 2018 The study has been completed in Austria.